| MA |
Report |
Net revenue growth (Q2 2026, reported/ccy-neutral) |
BEAT |
pred ~+12.3% to $9.16B vs. cons +11.5% to $9.068B |
MEDIUM |
| MA |
Report |
Adjusted EPS (Q2 2026) |
BEAT |
pred ~$4.88 vs. cons $4.77 |
MEDIUM |
| MA |
Report |
Cross-border volume growth, local currency (Q2 2026) |
MISS |
pred ~10% vs. cons ~12% (implied by guided 'progressive recovery' base case) |
LOW |
| MA |
Guide |
FY2026 net revenue growth, currency-neutral |
UNCHANGED |
guide ~11.5% (high end of low-double-digits) vs. cons ~11.5% (FY2026) |
MEDIUM |
| MA |
Guide |
Cross-border travel growth / recovery pace into Q3 |
LOWER |
guide ~7-8% Q3 travel-linked cross-border growth vs. prior implied recovery to ~11% (Q3 2026) |
MEDIUM |
| MA |
Guide |
Q3 2026 operating expense growth, currency-neutral |
UNCHANGED |
guide ~11% vs. cons ~11% (Q3 2026) |
LOW |
| MA |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.0% |
— |
MEDIUM |
| MA |
Return |
5-day cumulative residual |
-2.5% (FADE) |
Stock rallied ~12% into the print (with a sharp +5% move in the final week of July) pricing a clean beat-and-hold; even a headline EPS/revenue beat is likely accompanied by an admission that the Middle East conflict re-intensified rather than resolved during Q2, pushing out the previously-guided H2 cross-border travel recovery. That implies analysts trim out-quarter cross-border/travel and yield assumptions even as they nudge near-term estimates up for the beat, a net negative revision mix. Combined with an already-elevated valuation after the run-up and Visa's own muted stock reaction despite a beat-and-raise (initial AH dip before flattening), the more likely path is an initial soft/negative reaction that fades further over the week as the market digests delayed cross-border normalization and unchanged-to-cautious FY guidance. |
LOW |